Shares of Aradigm Corp. (NASDAQ:ARDM) have earned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Analysts have set a 1 year consensus price target of $26.00 for the company, according to Zacks. Zacks has also assigned Aradigm Corp. an industry rank of 88 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research upgraded shares of Aradigm Corp. from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research note on Wednesday, August 24th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Shares of Aradigm Corp. (NASDAQ:ARDM) traded down 0.96% during midday trading on Wednesday, reaching $5.18. The company’s stock had a trading volume of 5,447 shares. The firm’s market cap is $76.57 million. The stock’s 50 day moving average price is $4.65 and its 200 day moving average price is $4.48. Aradigm Corp. has a one year low of $2.60 and a one year high of $7.83.

Aradigm Corp. (NASDAQ:ARDM) last posted its earnings results on Wednesday, August 10th. The company reported ($0.59) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.59). Aradigm Corp. had a negative net margin of 670.67% and a negative return on equity of 147.53%. Analysts predict that Aradigm Corp. will post ($1.92) earnings per share for the current year.

A hedge fund recently raised its stake in Aradigm Corp. stock. Goldman Sachs Group Inc. raised its stake in Aradigm Corp. (NASDAQ:ARDM) by 26.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 30,301 shares of the company’s stock after buying an additional 6,382 shares during the period. Goldman Sachs Group Inc. owned about 0.21% of Aradigm Corp. worth $135,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 44.27% of the company’s stock.

About Aradigm Corp.

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.

5 Day Chart for NASDAQ:ARDM

Get a free copy of the Zacks research report on Aradigm Corp. (ARDM)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aradigm Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corp. and related companies with's FREE daily email newsletter.